Research programme: serotonin 2 receptor antagonists - AnaMar

Drug Profile

Research programme: serotonin 2 receptor antagonists - AnaMar

Alternative Names: AM260; AM260 TASS; Am260, TASS; AMAP 312; AMAP332

Latest Information Update: 03 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AnaMar Medical
  • Developer AcurePharma; AnaMar AB
  • Class Small molecules
  • Mechanism of Action Serotonin 2 receptor antagonists; Serotonin 2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Inflammatory pain; Osteoarthritis; Rheumatoid arthritis
  • Research Idiopathic pulmonary fibrosis

Most Recent Events

  • 03 Feb 2015 Research programme: serotonin 2 receptor antagonists - AnaMar is available for licensing as of 03 Feb 2015.
  • 03 Feb 2015 Early research in Idiopathic pulmonary fibrosis in Sweden (unspecified route)
  • 30 Oct 2014 Preclinical trials in Inflammatory pain in Sweden before October 2014 (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top